Novohope EYES+ oral film for pet eye care and tear stain control, tested to US FDA 21 CFR 175.300 requirements.

Pet Health Supplements: Evaluating Oral Film Manufacturing Partners for the Long Term

The pet health supplement market is growing, but the real challenge for brands is not just which ingredients to use—it's choosing a delivery system that pets will accept and a manufacturing partner that can deliver quality at scale. Oral dissolvable films (ODF) and orally disintegrating tablets (ODT) are emerging as formats worth serious evaluation.

The Growing Demand for Pet Health Supplements

Pet owners are treating their animals as family members, and this shift is reflected in the market for pet health products. Grand View Research estimates the global pet supplements market at approximately USD 2.8 billion in 2025, with growth to USD 4.6 billion projected by 2033. Mordor Intelligence's narrower dietary supplement segment is even larger, expected to reach USD 5.11 billion by 2026. North America remains the largest consumer, holding a 48.1% share in 2025, while Asia-Pacific is emerging as the fastest-growing region due to rising pet humanization and healthcare expenditure in China and India.

This expansion is creating new shelf space for functional pet supplements—products that target specific conditions such as joint health, digestion, calming, eye care, and weight management. At the same time, it is intensifying competition. To stand out, brands need product formats that combine efficacy with ease of use. This is where oral film technology has started to play a role.

The Administering Challenge: Why Pets Reject Traditional Formats

One of the least discussed but most critical problems in pet supplements is administration. Traditional pet medicines and supplement foods often come as pills, chunks, or powders that pets can smell, taste, or feel as foreign objects. According to Novohope's product comparison data, this can trigger physiological resistance—pets may vomit, refuse to swallow, or actively resist the feeding process.

For owners, the emotional toll is real. They are caught between forceful methods that may harm the pet and gentle approaches that fail. Some pet hospitals even charge separately for feeding assistance, which reflects how time-consuming the process has become. This administration problem creates a drop-off in compliance: even if the owner buys the supplement, the pet may not receive the full dose, reducing the product's chances of working.

Oral Dissolvable Films: A Format Designed Around Pet and Owner Needs

Oral dissolvable films offer a way around the first and most stubborn barrier: the pet's mouth. These ultra-thin strips dissolve quickly on the tongue or oral mucosa, leaving little room for the pet to reject the product. Novohope's films dissolve in about 10 seconds, and the soft, thin matrix is designed to minimize the “foreign particle” sensation.

This format has a direct absorption benefit. Active ingredients delivered through the oral mucosa can achieve absorption rates of up to 95%, according to Novohope, compared to 25–35% for traditional medicine absorbed through the gastrointestinal tract. Higher absorption means the active ingredients are more likely to reach systemic circulation, which may allow for lower doses or more reliable effects.

The format also fits a busy owner's routine. It can be given at home, outdoors, or anywhere, with no need for water or food. Novohope's maintenance comparison suggests that feeding with oral films is 5 to 10 times faster than traditional methods. The company also notes a 10–15% cost advantage over comparable traditional products, though this will vary by market and order structure.

Manufacturing Partnerships in the Oral Film Space

For brands entering this space, the critical question is whether they can find a manufacturer with the technical skill to formulate stable films and the operational discipline to produce them consistently. Novohope is a pet health supplement manufacturer that focuses on oral fast-dissolving formats, offering both ODF and ODT lines under its own brand as well as through OEM/ODM collaborations.

Novohope positions itself around “root-cause restoration” and “biorhythmic sync,” which in practice translates into target-specific nutrient matrices. The company's product line includes seven series, each designed for a major pet health concern. This breadth means that an emerging brand can launch a single product or expand into a full portfolio while keeping a consistent oral film format across all SKUs.

Technical Anatomy of Fast-Dissolving Oral Films and Tablets

The base technology is the oral fast-dissolving matrix. In Novohope's system, this matrix is combined with condition-specific nutrients such as Glucosamine HCl, Taurine, L-theanine, or probiotics, then formed into either a film (ODF) or a tablet (ODT).

Both forms are designed to dissolve rapidly in the mouth without water, but they differ in construction. Films are wafer-thin and flexible; tablets are small, orally disintegrating units that break down quickly on contact with saliva. This difference can influence product design, packaging, and the range of ingredient matrices that can be used.

Developing a stable oral film is a formulation challenge. The polymer matrix must protect active ingredients, mask unpleasant tastes, and dissolve consistently. It requires a laboratory and production environment that can control thickness, uniformity, and residual solvents. Novohope's technical team includes professional medical and technical experts, and the company has a technical cooperation with Vashere Life Laboratory, an institution linked to Nobel Prize-winning research. This kind of scientific support is a significant differentiator in a market where many supplement factories are dry powder blenders rather than film specialists.

Quality Control and Certifications as Supply Chain Fundamentals

Facility registration process flow at Novohope's pet supplement manufacturing site.

In long-term OEM relationships, quality consistency is the foundation. Novohope reports a mature factory quality control system, and every product must pass strict quality and product certifications before it can be sold. The company holds FDA Food Registration, and has formulations tested against US FDA 21 CFR 175.300, which addresses food-contact materials.

For buyers, the presence of a documented quality system matters at the sourcing audit stage. Novohope's procurement options include pre-shipment full inspection, third-party authoritative testing, and a Certificate of Analysis (COA) for qualifying orders. That provides an independent check beyond the manufacturer's own claims.

Product Line Coverage: From Tear Stain Care to Weight Management

FDA Food Registration certificate held by Novohope's pet supplement manufacturing facility.

The range of Novohope's series illustrates how oral film formats can be applied across many pet health categories:

EYES+ is positioned for eye care and tear stain reduction, with ingredients such as Taurine, NAC, Lutein and Zeaxanthin, and Silybin (SAMe). The tear stain segment has shown strong e-commerce traction, with leading products reportedly reaching high monthly volumes in markets like the U.S.

BONE+ targets joint and mobility support, combining Glucosamine HCl, Hydrolyzed Collagen Peptides, and Undenatured Type II Collagen. This is a core category for aging pets.

CALM+ uses alpha-casozepine, L-theanine, and Pediococcus acidilactici to support relaxation and stress management—especially relevant for pets in urban environments.

PROBIO+ addresses digestive health with Bacillus coagulans (GBI-30, 6086), pasteurized Akkermansia muciniphila as a postbiotic, and prebiotics GOS and XOS.

HEART+ and FIT+ cover cardiovascular support and weight management, with ingredients such as Coenzyme Q10, Taurine, L-Carnitine, and Vitamin E.

COAT+ rounds out the line with a focus on coat and skin health, using nutrients such as DHA and Biotin, N-Acetylglucosamine, and Sodium Hyaluronate.

This lineup gives retail buyers and distributors an opportunity to bundle products into a wellness portfolio. Instead of managing multiple vendors for different supplement types, a brand can concentrate its SKUs under one supplier with a unified format story.

Market Trends and the Shift Toward Functional Pet Supplements

Oral film technology is still emerging in the pet sector. Market Reports World notes that innovation is focusing on disintegration times below 25 seconds and palatability improvements of up to 47%. Novohope's 10-second dissolution places it ahead of that benchmark, but the larger trend is clear: the industry is moving toward faster, more taste-masked delivery systems.

The commercial logic is also supported by the structure of today's e-commerce market. Shelf space is becoming more competitive, and supplements that are easy to describe and demonstrate—like a film that dissolves in seconds—have a marketing advantage. The format helps differentiate a product on a crowded platform, and it reduces the likelihood of negative ownership experiences that can damage a brand's reputation.

From a compliance perspective, the U.S. market continues to emphasize quality standards such as the NASC Quality Seal, which requires good manufacturing practices and labeling audits. While Novohope's current published certifications include FDA Food Registration and US FDA 21 CFR 175.300 testing, buyers should independently verify certifications against their target market's requirements.

Comparison: Oral Films vs. Traditional Supplement Formats

The decision between oral films and traditional formats is not always binary. Oral films excel in speed, absorption, and user experience. However, there are boundaries. Some active ingredients are not compatible with the polymer matrices used in films, particularly at very high doses. Ingredients that require controlled release in the gastrointestinal tract may also need a more traditional coating or capsule.

There is also a manufacturing constraint. Not every factory has the laminating and drying lines needed to produce ODF, nor the formulation expertise to achieve uniform drug content. For brands, this means the supplier selection process becomes more technical than a typical “off-the-shelf” supplement order. The cost difference can be favorable—Novohope indicates its products are about 10–15% less costly than traditional formats—but that number must be validated against logistics, packaging, and market-specific duties.

In short, oral films are not a universal replacement, but for a large share of pet supplement categories, they are a strong alternative. A balanced supplier strategy might combine oral films for daily-use supplements and traditional formats for specialized high-dose requirements.

Procurement in Practice: MOQ, Delivery, and Payment Flexibility

Long-term partnerships are built on practical terms. Novohope offers two procurement models to accommodate different stages of growth. The low-order model has a minimum of just 1 unit, uses DDP delivery, includes pre-shipment full inspection and a COA-quality report, and requires full payment before shipment. This allows new market entrants to test products without committing to large volumes.

The volume model raises the minimum to 1000 boxes per SKU, ships on FOB or CIF terms, includes pre-shipment testing, and uses a 50/50 payment split (50% advance, 50% before shipment). This model is designed for established distributors who plan regular replenishment. Having both options on the table helps align the supplier's operations with a buyer's cash flow and risk appetite.

It is worth noting that order size affects more than price. It also determines the level of upstream testing and documentation. For a new brand, paying for the higher-touch inspection process can be a worthwhile insurance policy in the early days.

Future Outlook: Human-Grade Pet Nutrition and Scientific Validation

As pet owners become more educated, they are increasingly looking for the same quality standards they expect in human supplements. This is pushing pet supplement manufacturers toward “human-grade” ingredients, transparent labeling, and scientifically supported formulas. Novohope's stated focus on biomedical technology and root-cause restoration is consistent with this direction.

The next phase of the market may involve more personalized and condition-specific products. Oral film formats are well suited for this, because they can be made in compact, single-dose forms with precise ingredient amounts. R&D partnerships, like Novohope's collaboration with Vashere Life Laboratory, are likely to become more common as brands seek to differentiate through credible science rather than just artful marketing.

For distributors, the key will be picking partners who can evolve with the market. A manufacturer with a strong film platform, a broad product portfolio, and a flexible procurement model gives a brand room to grow without forcing it to switch suppliers as demand changes.

FAQ